The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
追加情報Neut: Use at a concentration of 0.1 µg/ml.
Human MCP1 is tested for its ability to neutralize the chemoattractant activity of rhMCP1 for human monocytes. The ND50 of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of rhMCP1 that was present at a concentration just high enough to elicit a maximum response.
In this bioassay, rhMCP1 was preincubated with various dilutions of the antibody for 1 hour at 37 °C in a 96-well microtiter plate. Then, the MCP1 antibody solution containing rhMCP1 at a final concentration of 0.1 µg/ml was transferred to the lower compartment of a 96-well chemotaxis chamber. The chemotaxis chamber was assembled using a PVP-free polycarbonate filter and the monocytes were added to the top chamber. The chamber was incubated for 90 minutes at 37 °C in a 5% CO2 humidified incubator. The chamber was disassembled and the filter fixed and stained. The optical density of the filter, which is proportional to the number of cells that migrated across the filter, was read with a microtiter plate reader set at 540 nm.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
機能Chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.
配列類似性Belongs to the intercrine beta (chemokine CC) family.
翻訳後修飾Processing at the N-terminus can regulate receptor and target cell selectivity. Deletion of the N-terminal residue converts it from an activator of basophil to an eosinophil chemoattractant.